AVP-786: Progress in the Use of Deuterium in Alzheimer’s Treatment

In the continuing clinical trials, Avanir Pharmaceuticals’ drug, AVP-786, is showing the progress being made in the use of deuterium in medical science. Successes like this pharmaceutical will continue to drive forward product development centered around the unique properties of deuterium by the world’s drug developers via their innovative R&D. Furthermore, advancements like this in the multi-billion dollar pharmaceutical industry are significantly improving the quality of patients lives.